

DR LI REN, A SENIOR CAR T EXECUTIVE FROM BMS, JOINS CHIMERIC THERAPEUTICS AS VICE PRESIDENT, TECHNICAL OPERATIONS

HIGHLIGHTS

- Dr Li Ren joins Chimeric with a focus on advancing the technical operations of the Company's assets
- Dr Ren brings extensive cell therapy experience, most recently from Bristol-Myers Squibb (BMS) where she oversaw technology transfers from Juno Therapeutics
- Prior to joining BMS, Dr Ren spent nearly 15 years at Celgene and Celgene Cellular Therapies (CCT), leading chemistry, manufacturing and control (CMC) efforts to advance CAR T, TCR and NK cell therapies to clinic

Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), a clinical stage cell therapy company focused on bringing the promise of cell therapy to patients with cancer, is pleased to announce the appointment of Dr Li Ren as Vice President, Technical Operations.

Dr Ren has nearly 20 years of experience developing and advancing cell therapy drug candidates from the pre-clinical stage through to commercial licensure. She has led the process and analytical development of multiple allogeneic & autologous cell therapy products over her career, including CAR T cells, TCR cells, NK cells and mesenchymal-like stem cells.

Dr Ren joins Chimeric from Bristol-Myers Squibb (BMS) where she most recently oversaw the technology transfers of Juno cell therapy pipeline products to BMS manufacturing facilities and provided technical support for both GMP manufacturing and quality control (QC) testing to enable clinical trials.

Over the course of her career Dr Ren has also supported multiple IND submissions for pipeline products to enable clinical trials and designed and led process & analytical validation programs in support of commercial registration filing.

In her role at Chimeric, Dr Ren will be responsible for leading the process and analytical development of CLTX CAR T and ensuring the successful technology transfer to a clinical manufacturing organisation of CLTX CAR T to enable future clinical trials.

Chimeric's Chief Operating Officer, Jennifer Chow said: "Chimeric is incredibly excited and very fortunate to have Dr Ren joining us. Technical operations is a critical component of cell therapy development and finding the expertise and experience that Dr Ren brings is rare. Dr Ren joining Chimeric will further enhance our internal cell therapy expertise, enabling us to advance and accelerate the development of our assets and growth of our company."

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for patients with cancer.

Chimeric believes that cellular therapies have the potential to cure cancer and that by combining their expertise in the development and commercialization of cell therapies with the world's most innovative scientists and science, they will be able to bring the promise of cell therapy to life for more patients.

Chimeric Therapeutics has licensed the exclusive global rights to intellectual property covering the CLTX CAR T cell therapy which is currently in development for patients with progressive and recurrent glioblastoma and is also being investigated for development in patients with other solid tumors such as melanoma, small cell lung cancer, prostate cancer and colorectal cancer.

Chimeric Therapeutics is also currently actively engaged in enhancing their pipeline with innovative cell therapies for patients with cancer.

CONTACT

Investors

Jennifer Chow
Chief Operating Officer
P: 908-723-8387
E: jchow@chimerictherapeutics.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au